Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-992: pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for newly diagnosed muscle-invasive bladder cancer
MOH_2020-02-10_008609Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Merck & Co. Primary endpoint: Intact bladder event-free survival. Started Jan 2020; status: active, not recruiting.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on MOH_2020-02-10_008609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-02-10_008609.